Systematic Review
Impact of antibiotic treatment duration on community-acquired pneumonia in children: a systematic review
1Medicine Department, Universidad de las Américas, Ecuador
2Medicine Department, Universidad Técnica de Ambato, Ecuador
3Medicine Department, Universidad Iberoamericana, Quito, Ecuador
4Medicine Department, Ministry of Public Health, Ecuador
5Instituto Superior Tecnológico Riobamba, Ecuador
Received: 03 March 2024
Revised: 15 March 2024
Accepted: 18 March 2024
*Correspondence:
Dr. Josselyn N. V. Enríquez,
E-mail: nickythg3estudiar@gmail.com
Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
The treatment of pediatric community-acquired pneumonia (CAP) with antibiotics is important due to its substantial global health impact. To support clinical practice and antibiotic stewardship, this narrative review investigates the effects of the length of antibiotic therapy on the outcomes of childhood CAP. A thorough search of PubMed, Scopus, and Google Scholar produced English articles published in the last ten years (2019–2024) and looked at the connection between the length of antibiotic therapy and the outcomes of community-associated pneumonia in children. There is increasing evidence to support the similarity of shorter and longer antibiotic regimens for treating juvenile community-acquired pneumonia. Research continuously shows that shorter periods of antibiotic therapy—usually five days—produce similar clinical results as lengthier regimens that last seven to 10 days. Furthermore, emphasis is placed on tailored treatment plans that take into account the child's age, the severity of the symptoms, and regional trends of antibiotic resistance. The included studies, albeit observational and retrospective, provide important insights into the safety, effectiveness, and consequences of various antibiotic regimens in the therapy of pediatric CAP. This review emphasizes the significance of evidence-based strategies to maximize antibiotic treatment for pediatric CAP, while also noting research limitations. More research is required to enhance treatment methods and results for kids with CAP. This includes carefully planned randomized controlled trials and integrated diagnostic tools.
Keywords: Antibiotic, Duration, Community-acquired pneumonia, Children
INTRODUCTION
Pediatric community-acquired pneumonia (CAP) is a prevalent disease. Due in part to decreasing childhood vaccination rates, the prevalence of CAP has decreased in high-income nations but remains a significant burden for patients and health systems in low- and middle-income countries.1 According to data from the World Health Organization in 2022, pneumonia is the cause of 14% of fatalities in children under the age of five and 22% of deaths in children between the ages of one and five.2
Respiratory syncytial virus is the most frequent viral cause of pediatric CAP, followed by influenza viruses. Pediatric bacterial CAP is mostly caused by Streptococcus pneumoniae.1,3 Haemophilus influenzae type B, Staphylococcus aureus, Mycoplasma pneumoniae, and Chlamydia pneumoniae are further bacterial causes.3
The most often researched treatment length for pediatric CAP is 10 days, according to 2011 recommendations from the Infectious Diseases Society of America and the Pediatric Infectious Diseases Society. However, shorter durations may work for kids with moderate illness who are treated in outpatient settings.3 In a similar vein, the 2015 Canadian Paediatric Society statement on uncomplicated CAP emphasizes that hospitalized children need antibiotic treatment for seven to ten days; however, outpatients may only need five days.1 Recent research suggests that the traditionally recommended 10-day course of antibiotic therapy for outpatient care of uncomplicated CAP may not be essential, raising questions about the ideal length of antibiotic treatment.4
Debatable has been the ideal length of therapy for CAP in high-income nations. In 2014, a systematic review was published that examined the effectiveness of a shorter treatment period for CAP, using data from randomized controlled trials (RCTs). Of the eight RCTs, only one came from a high-income nation, and the majority did not compare the current treatment advice with shorter antibiotic treatments.5 The most current systematic review, which did not contain a meta-analysis, included 11 trials, eight of which were from poor nations. It came to the conclusion that further research from high-income nations was required to ascertain the efficacy and safety of shorter antibiotic courses for children.6
In principle, there are various advantages to using shorter antibiotic treatments for juvenile instances of CAP compared to the ones that are currently being used. Reduced exposure to antibiotics for both pathogenic and non-pathogenic microorganisms of normal flora lessen the selection pressure for the establishment of resistant strains, which may prevent the development of antibiotic resistance. Furthermore, unnecessarily lengthy regimens raise the possibility of side effects, such diarrhea, which is typical of young infants receiving antibiotics.7
This narrative literature review aims to explore the current evidence regarding the impact of antibiotic treatment duration on CAP outcomes in children, addressing key questions surrounding treatment duration, guidelines about the treatment, and implications for clinical practice and future research.
METHODS
Using reliable scholarly sources like PubMed, Scopus, and Google Scholar, we followed a methodical process to do an extensive evaluation of the literature. We used recognized approaches from related narrative review publications due to the intricacy of the issue, which is the effect of antibiotic treatment duration on CAP outcomes in children.
"Antibiotic treatment duration," "antibiotic therapy," "community-acquired pneumonia," "pediatric pneumonia," and similar variants were among the key search phrases that were used. To hone in on pertinent research and improve search queries, Boolean operators (AND, OR) were used.
Inclusion and exclusion criteria
Peer-reviewed English-language publications over the last ten years (2014–2024) that looked at the connection between pediatric populations' outcomes from antibiotic therapy and length were the ones we concentrated on include. The influence of different antibiotic regimens on treatment success, relapse rates, and antibiotic-related problems were examined in studies conducted in both outpatient and inpatient settings.
Case studies, editorials, and letters to the editor were not included in the study because they lacked methodological rigor. Also excluded from consideration for inclusion were any publications that did not specifically address how the length of antibiotic therapy affects the outcomes of CAP in children. After a preliminary screening of full-text papers based on titles and abstracts, these articles were carefully assessed for applicability and relevancy to the review.
Analysis and categorization
We used a systematic classification strategy to arrange and examine the material regarding the effect of antibiotic treatment duration on pediatric CAP outcomes. The review's main goal was to clarify how various antibiotic treatment durations affect pediatric CAP patients' clinical outcomes.
Analytical categories were created to investigate the safety, effectiveness, and consequences of different antibiotic treatment durations, from shorter courses (like five days) to longer courses (like ten days or more). The study focused on analyzing the outcomes of therapy, rates of recurrence, adverse events connected to antibiotics, and the use of healthcare resources for varying treatment durations.
To provide a thorough picture of the subject, our study concentrated on combining data from meta-analyses, randomized controlled trials, retrospective cohort studies, and systematic reviews. We hoped to provide insights into the ideal course of antibiotic treatment for pediatric CAP by organizing the evaluation around these analytical categories and emphasizing potential areas for further study and clinical practice concerns.
RESULTS
A total of 667 papers pertaining to "Impact of antibiotic treatment duration on community-acquired pneumonia in children" were found during the first literature search. After a thorough assessment of the abstracts and titles, 70 publications were deemed relevant, and their whole texts were obtained for further examination. Studies that failed to fulfil the predetermined inclusion criteria or did not explicitly examine the impact of the length of antibiotic therapy on pediatric community-acquired pneumonia were later eliminated. After this stringent screening procedure, 10 publications were finally judged appropriate for inclusion in the systematic review carried out for this study.
Guidelines for pneumonia treatment at home
Since bacterial and viral pneumonia cannot be consistently separated from one another, the BTS pneumonia recommendations propose that all children with a clinical diagnosis of pneumonia be treated with antibiotics.8 Antibiotics are not usually necessary for children under two years old who exhibit moderate symptoms, particularly if wheezing is present. However, if the child's symptoms worsen or his or her parents are concerned, they should be re-examined. As viral pathogens account for the vast majority of infections at that age, the IDSA pneumonia recommendations do not typically suggest antibiotics for preschool-aged children with CAP who come with moderate symptoms.3
Both recommendations suggest amoxicillin as the first line of treatment when using oral antibiotics since it is inexpensive, well-absorbed, and effective against most bacterial infections that cause CAP in children.8 The recommendation is not as much supported by scientific findings as it is by extensive and prolonged clinical experience. Amoxicillin substitutes include amoxicillin plus clavulanic acid, azithromycin or clarithromycin, first- or second-generation cephalosporins, but macrolides are not advised for monotherapy since Streptococcus pneumoniae is no longer sufficiently susceptible to them in many nations.3,9
However, Mycoplasma pneumoniae and Clamydophila (formerly known as Clamydia) pneumoniae are resistant to penicillins and cephalosporins. Doxycycline is effective against atypical bacteria in addition to macrolides, and it may be administered to children older than 8 years old.9 Doxycycline has two advantages over macrolides: it may be given intravenously and S. pneumoniae strains are less likely to be resistant to it than to macrolides.
Guidelines for pneumonia treatment at hospital
When treating a kid with pneumonia, intravenous antibiotics should be administered, especially if the youngster is unable to absorb oral medicines because of vomiting or other medical conditions. Parenteral ampicillin or G-penicillin is advised by the BTS and IDSA pneumonia recommendations for children who have had pneumococcal vaccines and who reside in an area where there isn't a significant prevalence of penicillin resistance in pneumococcal strains.8
Cefuroxime, ceftriaxone, or cefuroxime are the recommended intravenous antibiotics for people who have not received a pneumococcal vaccination, live in an area where invasive pneumococcal strains have high levels of penicillin resistance, or present with complicated pneumonia. In some carefully chosen cases, these antibiotics can be combined with vancomycin or fluoroquinolones.10
Impact of duration of treatment
In children with CAP, antibiotic regimens typically last seven to ten days, while shorter courses—five days—might work just as well. 168 toddlers older than six months who were hospitalized for CAP and underwent short-course antibiotic treatment lasting six days (median) and 271 children who got long-course medication lasting ten days or more were included in a retrospective one-center cohort research conducted in the United States.11 It seemed unlikely that children with milder symptoms of CAP would spontaneously recover, since inclusion in the analyses was restricted to those with clinical and radiographic criteria consistent with pneumonia. Treatment failure occurred in 4% of children, with no discernible differences between the two research groups.11
Following the PubMed search for references for this mini-review, a prospective, blinded, parallel-group, non-inferiority RCT research comparing five-day vs 10-day antibiotic course lengths was conducted in two Canadian centers in 2016–2019 and published in 201. A total of 281 kids between the ages of six months and ten years old (mean 2.6 years, males 57.7%) received outpatient treatment for CAP. The standard-care group got amoxicillin for ten days, whereas the short-course group received high-dose amoxicillin for five days, followed by a placebo for five days. In the short-course group, 101/114 (88.6%) and in the standard-care group, 99/109 (90.8%) showed clinical cure. In the per-protocol analysis, the short antibiotic treatment did not perform worse than the usual course. In the short-course group, clinical cure at 14–21 days was 108/126 (85.7%), whereas in the standard-care group, it was 106/126 (84.1%). No significant differences were found in intention-to-treat analyses. The authors came to the conclusion that for the treatment of previously healthy children with CAP who did not need hospitalization, short-course antibiotic therapy was equivalent to conventional care.12
Except for the outpatient Swiss and Canadian studies prospective studies on the length of antibiotic courses in CAP have only been conducted in developing, low-income nations. Such prospective trials are necessary even in high-income nations because, if effective and safe, cutting down on antibiotic therapy would significantly reduce antibiotic exposure, bacterial resistance to antibiotics, and associated costs for families and communities.12
4002 toddlers diagnosed at primary care centers in Pakistan between the ages of 2 and 59 months with tachypnea and non-severe CAP participated in a double-blind, placebo-controlled non-inferiority research. Treatment failure was the main consequence of the children's randomization between three-day amoxicillin and placebo treatments. The mean rate of treatment failure in cases was 2.3%, whereas in controls it was 4.9%, according to per-protocol studies. The pre-established threshold of non-inferiority was not met by the average between-group difference of 2.3% percentage points. In analyses using intention-to-treat, the outcomes were comparable. 3.1% of the amoxicillin group and 2.2% of the placebo group had relapses.13
In Malawi, a virtually comparable placebo-controlled trial was initiated. A total of 1126 kids between the ages of one and fifty-nine months were randomized to receive either a placebo or amoxicillin. However, after an interim analysis, the safety monitoring board decided to stop the trial since the placebo-treated controls had a treatment failure rate of 7.0%, while the patients experienced a rate of 4.0%. In adjusted analysis, the 3.0%-point difference was statistically significant. Even though the findings preferred amoxicillin therapy, by day four, 93% of patients receiving a placebo had improved, and by day 14, there was no difference in the number of failures and relapses between the case and control groups.14
An RCT on the length of amoxicillin therapy was conducted in Malawi with 3000 children between the ages of 2 and 59 months who were diagnosed with non-severe CAP according to WHO criteria and had chest recessions at primary care centers. By day six, the percentage of children who had not responded to therapy after three days of amoxicillin treatment was 5.9% in 1497 cases and 5.2% in 1503 cases. By day 14, the percentages of relapses were 12.5% and 10.8%, respectively. Though not statistically significant, the group differences did not approach the pre-established threshold of inferiority, and the five-day therapy was shown to be more beneficial.15
Children 6 months to 10 years old who presented with CAP (radiologic and clinical diagnosis) were also compared to receive 5 days and 10 days of high-dose amoxicillin (90 mg/kg/day split into 3 doses) in another placebo-controlled non-inferiority study conducted in two Canadian emergency rooms. The main goal of this research was to achieve a clinical cure under rigorous guidelines. As a result, several patients whose CAP improved after taking antibiotics were classified as having failed therapy, even if they would have otherwise been thought to have reacted well. As a result, the concept of clinical cure that doesn't call for further intervention was created as a supplementary definition. An analysis was conducted on 252 patients, with a mean age of 2.5 years. The intention-to-treat analysis revealed a rate of 93.5% in the 5-day group compared with 90.4% in the 10-day group for the clinical cure that did not need further intervention outcome (risk difference [RD]=0.028; 97.5% confidence limit [CL]=−0.038). The stringent per protocol analysis rates (which only included patients with radiographic CAP) were 95.0% and 94.0%, respectively (RD=−0.004; 97.5% CL=−0.071), whereas the per protocol analysis rates were 95.5% and 95.4% (RD=−0.006; 97.5% CL=−0.055). Therefore, compared to a 10-day therapy, a 5-day treatment was statistically noninferior.12
In a more recent multicenter, randomized, double-blind, placebo-controlled superiority trial, 380 patients with uncomplicated CAP (mean age 35.7 months) were randomized to receive high-dose amoxicillin for 5 or 10 days, amoxicillin-clavulanic acid combination (80 to 100 mg/kg/day divided into 2 doses), or cefdinir (12 to 16 mg/kg/day divided into 2 doses). Patients were randomized to receive a placebo or an extra 5 days of antibiotic therapy if they demonstrated clinical improvement after 5 days of treatment. The main result was the reaction modified for the length of antibiotic risk on days six through ten. After adjusting for the length of the antibiotic risk across a 5-day period, the estimated odds of a more desired response were 0.69 (95% CI 0.63 to 0.75) on days 6 to 10 and 0.63 (95% CI 0.57 to 0.69) on days 19 to 25. Therefore, the shorter time frame was better than the lengthier one. This study's shortcomings include its restricted relevance to children under the age of six, its lack of microbiological testing, and its inconsistent clinical diagnosis of CAP.16
Since most children responded well to a 5-day course of therapy, research into even shorter durations of time gained traction. In 2021, a multicenter, randomized, placebo-controlled, 4-arm non-inferiority trial was carried out in the UK and Ireland, involving 814 children older than 6 months. The trial compared the duration of treatment for uncomplicated clinically diagnosed CAP between three and seven days, and compared low- and high-dose oral amoxicillin (35 to 50 mg/kg/day divided into two doses) and 70 to 90 mg/kg/day divided into two doses. For both the 3-day and 7-day arms (12.5% versus 12.5%) and the low-dose versus high-dose comparison (12.6% versus 12.4%), the non-inferiority margin for the main endpoint of clinically recommended therapy within 28 days after beginning the study medication was satisfied. Nasopharyngeal samples from 42% and 29.5% of children, respectively, at baseline and therapy completion showed S. pneumoniae colonization. There were no samples found to contain S. pneumoniae that was resistant to penicillin, and the rates of side effects linked to antibiotics were comparable. Regarding the results of the nasopharyngeal swab, 3 days of therapy was not inferior to 7 days of treatment, even though the research did not examine the data depending on whether patients were already taking antibiotics at the time of their first hospital admission.17
In high-income nations, Kuitunen et al carried out a systematic review and meta-analysis centered on the ideal length of therapy for CAP in children older than six months. In their study, they contrasted shorter (3–5 days) with longer (7–10 days) antibiotic treatments for children who were outpatients. In comparison to the lengthier (present) prescription of 7-10 days, a short antibiotic treatment duration of 3-5 days was determined to be as effective and safe across the four included trials, which included 1541 children. There was no statistically significant difference between shorter and longer treatment durations, as shown by the 0.1% (95% confidence range, -3.0% to 2.0%) risk difference for treatment failure, which is defined as the requirement for retreatment or hospitalization within a month. In addition, two trials with 1194 children evaluated adverse events associated with antibiotic therapy, showing a 0.0% (−5.0% to 5.0%) risk difference. The authors came to the conclusion that pediatric CAP may be treated with brief doses of antibiotics.18
Li et al finished another comprehensive review and meta-analysis of randomized controlled trials in 2022 that compared a shorter versus a longer course of antimicrobial treatment using the same antibiotic drug in children with non-severe CAP. The research found that, in terms of treatment failure and relapse rates, short-term therapy was not less effective than longer-term treatment, based on nine trials, seven of which had a short length of three days. The short course of therapy was shown to be non-inferior in a subgroup analysis of children ages 2 to 59 months, but it was not found to be non-inferior in older children (ages 5 to 10 years). The authors came to the conclusion that a brief course of antibiotic therapy is safe to administer and non-inferior to lengthier treatment for children with non-severe CAP between the ages of 2 and 59 months.19
In order to assess the clinical and laboratory results of short-course antibiotic therapy (3-day or 5-day) vs normal 10-day treatment in young children with community-acquired alveolar pneumonia, Greenberg and colleagues undertook a double-blind, randomized, placebo-controlled experiment. This was a two-stage trial; the first, a 3-day arm, was replaced with a 5-day arm because the failure rate was too high. The final analysis revealed that a 5-day treatment of oral amoxicillin at a high dosage was not less effective than a 10-day course in treating 6- to 59-month-old outpatients with community-acquired alveolar pneumonia. The 5-day and 10-day regimens had no failures; however, the 3-day regimen had an unsatisfactory failure rate. The 5-day and 10-day groups' secondary results were comparable, demonstrating the safety and effectiveness of the shorter treatment period.20
The cause of CAP was not identified, the antibiotic courses lasted no more than five days, and failure and recurrence rates were rather high. These investigations were conducted in developing, low-income nations. These are the explanations for why developed, high-income nations cannot immediately apply the outcomes. Even while amoxicillin was only slightly more effective than a placebo, these findings show that mild instances of CAP, which are often caused by viral CAP in children under the age of five, may be treated without the need for antibiotics.
DISCUSSION
A thorough analysis of the effect of the length of antibiotic therapy on the outcomes of CAP in children is provided by the narrative review. It summarizes research results from several studies, including as meta-analyses, randomized controlled trials (RCTs), retrospective cohort analyses, and systematic reviews, to clarify the safety and effectiveness of various antibiotic regimens.
The equivalency of shorter and longer antibiotic courses in the treatment of pediatric CAP is one of the main conclusions of the study. Studies, like the retrospective cohort study by Same et al consistently show that in terms of treatment failure and clinical cure rates, shorter courses of antibiotic therapy—typically lasting five days—are not inferior to lengthier courses lasting seven to ten days. The conventional treatment paradigms that supported extended antibiotic regimens are challenged by this data.11
Furthermore, the study emphasizes the significance of tailored treatment strategies depending on variables including the child's age, the severity of the symptoms, and regional antibiotic resistance tendencies. All children with clinical pneumonia should get antibiotics, according to guidelines as stated by Bradley et al and Harris et al. However, there are certain guidelines that advise careful consideration should be given to the selection and duration of antibiotics, particularly for preschool-aged children with mild symptoms.8
The paper also addresses how shorter antibiotic courses might minimize the development of antibiotic resistance, minimize antibiotic-related adverse effects, and maximize the use of healthcare resources. Shorter courses reduce the dangers associated with extended antibiotic exposure in addition to producing equivalent clinical results, as shown by studies such as Pernica et al.12
The study also emphasizes the need of doing further research to determine the best treatment lengths for different age groups and pneumonia severity levels. There is no information on the usefulness of shorter antibiotic courses for older children and those with severe pneumonia, even though the evidence currently available supports their use for non-severe case of community-acquired pneumonia in children between the ages of 2 and 59 months.14
Even though we conducted a comprehensive assessment, there are a few restrictions that should be noted. First, the bulk of the research that made up this review were observational or retrospective in nature, which made it more difficult to prove causation. Furthermore, variations in patient demographics, research methods, and outcome measures between studies may introduce bias and impair the generalizability of results. Moreover, research published in other languages or earlier may have been overlooked due to the emphasis on English-language publications during a certain time period.
Going ahead, further investigation is required to clarify the ideal length of antibiotic treatment for pediatric CAP. Robust randomized controlled studies contrasting various antibiotic regimens and durations in heterogeneous pediatric populations are necessary to provide superior data for therapeutic decision-making. Subsequent research endeavors need to delve into the plausible influence of the length of antibiotic therapy on patterns of antibiotic resistance, the structure of the microbiome, and the neurodevelopmental outcomes of children patients with community-associated pneumonia. Moreover, more accurate and customized therapeutic methods for pediatric CAP management may be made possible by the use of cutting-edge diagnostic technologies including biomarkers and imaging modalities. In general, more research is needed to enhance antibiotic treatment approaches and the prognosis of kids with CAP.
CONCLUSION
Our analysis draws attention to the increasing amount of data that suggests shorter and longer antibiotic regimens may be used equally to treat pediatric CAP. Research continuously shows that five days is a common period of antibiotic treatment, and that extended courses (seven to ten days) have equivalent clinical effects. In order to maximize patient outcomes while lowering the hazards connected with antibiotic misuse, this study challenges traditional treatment paradigms and emphasizes the need of using evidence-based practices. Personalized treatment plans that take into account the child's age, the severity of the symptoms, and regional trends of antibiotic resistance are other important points we want to highlight. Guidelines state that all children with clinical pneumonia should get antibiotics, but they also support careful consideration when deciding which medicines to take for how long, particularly in the case of preschool-aged children who have mild symptoms.
Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required
REFERENCES
- 1. Le Saux N, Robinson JL; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management. Paediatr Child Health. 2015;20(8):441-5.
- 2. McIntosh K. Community-acquired pneumonia in children. N Engl J Med. 2002;346(6):429-37.
- 3. Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-76.
- 4. Agarwal G, Awasthi S, Kabra SK, Kaul A, Singhi S, Walter SD; ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ. 2004;328(7443):791.
- 5. Ben-Shimol S, Levy-Litan V, Falup-Pecurariu O, Greenberg D. Evidence for short duration of antibiotic treatment for non-severe community acquired pneumonia (CAP) in children - are we there yet? A systematic review of randomised controlled trials. Pneumonia (Nathan). 2014;4:16-23.
- 6. Korppi M. Antibiotic therapy in children with community-acquired pneumonia. Acta Paediatr Int J Paediatr. 2021;110(12):3246-50.
- 7. Curran J, Lo J, Leung V, Brown K, Schwartz KL, Daneman N, et al. Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis. Clin Microbiol Infect. 2022;28(4):479-90.
- 8. Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: Update 2011. Thorax. 2011;66:2.
- 9. Tapiainen T, Aittoniemi J, Immonen J, Jylkkä H, Meinander T, Nuolivirta K, et al. Finnish guidelines for the treatment of community-acquired pneumonia and pertussis in children. Acta Paediatr Int J Paediatr. 2016;105(1):39-43.
- 10. de Benedictis FM, Kerem E, Chang AB, Colin AA, Zar HJ, Bush A. Complicated pneumonia in children. Lancet. 2020;396(10253):786-98.
- 11. Same RG, Amoah J, Hsu AJ, Hersh AL, Sklansky DJ, Cosgrove SE, et al. The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. J Pediatric Infect Dis Soc. 2021;10(3):267.
- 12. Pernica JM, Harman S, Kam AJ, Carciumaru R, Vanniyasingam T, Crawford T, et al. Short-Course Antimicrobial Therapy for Pediatric Community-Acquired Pneumonia: The SAFER Randomized Clinical Trial. JAMA Pediatr. 2021;175(5):475-82.
- 13. Jehan F, Nisar I, Kerai S, Balouch B, Brown N, Rahman N, et al. Randomized Trial of Amoxicillin for Pneumonia in Pakistan. N Engl J Med. 2020;383(1):24-34.
- 14. Ginsburg AS, Mvalo T, Nkwopara E, McCollum ED, Ndamala CB, Schmicker R, et al. Placebo vs Amoxicillin for Nonsevere Fast-Breathing Pneumonia in Malawian Children Aged 2 to 59 Months: A Double-blind, Randomized Clinical Noninferiority Trial. JAMA Pediatr. 2019;173(1):21.
- 15. Ginsburg AS, Mvalo T, Nkwopara E, McCollum ED, Phiri M, Schmicker R, et al. Amoxicillin for 3 or 5 Days for Chest-Indrawing Pneumonia in Malawian Children. N Engl J Med. 2020;383(1):13-23.
- 16. Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, et al. Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial. JAMA Pediatr. 2022;176(3):253-61.
- 17. Bielicki JA, Stöhr W, Barratt S, Dunn D, Naufal N, Roland D, et al. Effect of Amoxicillin Dose and Treatment Duration on the Need for Antibiotic Re-treatment in Children With Community-Acquired Pneumonia: The CAP-IT Randomized Clinical Trial. JAMA. 2021;326(17):1713-24.
- 18. Kuitunen I, Jääskeläinen J, Korppi M, Renko M. Antibiotic Treatment Duration for Community-Acquired Pneumonia in Outpatient Children in High-Income Countries—A Systematic Review and Meta-Analysis. Clin Infect Dis An Off Publ Infect Dis Soc Am. 2023;76(3):e1123.
- 19. Li Q, Zhou Q, Florez ID, Mathew JL, Shang L, Zhang G, et al. Short-Course vs Long-Course Antibiotic Therapy for Children With Nonsevere Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. JAMA Pediatr. 2022;176(12):1199-207.
- 20. Greenberg D, Givon-Lavi N, Sadaka Y, Ben-Shimol S, Bar-Ziv J, Dagan R. Short-course antibiotic treatment for community-acquired alveolar pneumonia in ambulatory children: A double-blind, randomized, placebo-controlled trial. Pediatr Infect Dis J. 2014;33(2):136-42.